ATHOS-3
Angiotensin II for the Treatment of High-Output Shock
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 321 patients with catecholamine-resistant vasodilatory shock, synthetic angiotensin II improved MAP response at 3 hours compared with placebo, without proven mortality benefit.
N
321
Design
Double-blind RCT
Endpunkt
MAP response (≥10 mm Hg or ≥75 mm Hg) at 3 hours
Relevanz
3
Ergebnis69.9% vs 23.4% (OR 7.95; p<0.001). 28-d mortality 46% vs 54% (HR 0.78; p=0.12).
Khanna A, et al. N Engl J Med. 2017;377(5):419-430. 10.1056/NEJMoa1704154
Diskussion & Kritik
FDA-approved 2017 for catecholamine-resistant shock; reserve for refractory cases at experienced centres.